INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
批准号:
7742240
负责人:
RICHARD H. EBRIGHT
金额:
$58.22万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2011-12-31
关键词:
AddressAffectAnti-Bacterial AgentsBacterial InfectionsBacterial RNABindingBiological FactorsBiological WarfareBioterrorismClinicalCloningComplexCrystallographyDNADNA-Directed RNA PolymeraseDevelopmentElementsEscherichia coliEvaluationExhibitsFutureGene ClusterGenetic TranscriptionGrowthLactonesMediatingMolecular CloningMolecular ConformationPolymerasePublic HealthPyronesRNA Polymerase IRNA Polymerase IIRNA Polymerase IIIReactionResearch PersonnelResistanceRifabutinRifampinScreening procedureStructureThermus thermophilusTranscription InitiationWorkbaseinhibitor/antagonistnovelprogramsresistant strainrifapentinesingle moleculesingle-molecule FRETsmall moleculetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Preliminary work establishes that three natural products-the polyketide-derived a-pyrone myxopyronin, the
Dolyketide-derived a-pyrone corallopyronin, and the polyketide-derived macrocylic lactone ripostatin-inhibit
Dacterial RNA polymerase (RNAP) through interactions with the RNAP "switch region," a structural element
that mediates conformational changes required for RNAP to bind and retain the DMAtemplate in
transcription. The compounds do not inhibit eukaryotic RNAP I, RNAP II, or RNAP III. The compounds
ootently inhibit Gram-positive and Gram-negative bacterial growth, exhibit no cross-resistance with the
nhibitors of bacterial RNAP in current clinical use in therapy of bacterial infection (therifamycin antibacterial
agents, rifampicin, rifapentine, and rifabutin), and exhibit no cross-resistance with other inhibitors of bacterial
RNAP under evaluation for future clinical use in therapy of bacterial infection.
The proposed work wilt use x-ray crystallography, ensemble and single-molecule fluorescence resonance
energy transfer, single-molecule nanomanipulation, molecular cloning, surrogate-host expression,
structure-based screening, and de novo screening, to address four specific aims:
Specific Aim 1: Determination of structures of complexes of RNAP with switch-region-target inhibitors
Specific Aim 2: Determination of mechanisms of inhibition of RNAP by switch-region-target inhibitors
Specific Aim 3: Cloning, characterization, and surrogate-host expression of biosynthetic gene clusters
for switch-region-target inhibitors
Specific Aim 4: Identification and characterization of novel switch-region-target inhibitors
The results will enable development of new broad-spectrum antibacterial agents that will be effective against
bacterial strains resistant to currently used antibacterial agents. As such, the results will have direct
relevance to public health and to development of countermeasures against bacterial strains that could be
used in biowarfare or bioterrorism. In addition, the results will contribute to understanding RNAP structure
and function and will provide tools for analysis of RNAP structure and function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bacterial Transcription Complexes
-
批准号:10388566
-
项目类别:
-
资助金额:$5.1万
-
财政年份:2021
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10394990
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10613893
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8978290
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8603843
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8782465
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8474439
-
项目类别:
-
资助金额:$104.89万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8476980
-
项目类别:
-
资助金额:$114.02万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8288777
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8105468
-
项目类别:
-
资助金额:$120.94万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8697004
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:7989018
-
项目类别:
-
资助金额:$124.8万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
BACTERIAL TRANSCRIPTION COMPLEXES
-
批准号:7932650
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2009
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7337094
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7187263
-
项目类别:
-
资助金额:$59.85万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7540990
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:8009521
-
项目类别:
-
资助金额:$55.96万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6046298
-
项目类别:
-
资助金额:$15.85万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6363271
-
项目类别:
-
资助金额:$16.32万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:2668516
-
项目类别:
-
资助金额:$14.93万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
海外基金